Abcellera Biologics Inc. Stock
€2.88
Your prediction
Financial data and news for Abcellera Biologics Inc.
sharewise wants to provide you with the best news and tools for Abcellera Biologics Inc., so we directly link to the best financial data sources.
Financials
News
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575
AbCellera (Nasdaq: ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL575, an investigational antibody
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
AbCellera (Nasdaq: ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL635, an investigational antibody
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
AbCellera (Nasdaq: ABCL) today announced that the United States Court of Appeals for the Federal Circuit (CAFC) has by a Rule 36 Order affirmed judgment of validity of its U.S. Patent No
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting
AbCellera (Nasdaq: ABCL) today announced preclinical data on ABCL575, which will be presented as a poster at the Society for Investigative Dermatology (SID) Annual Meeting at the Hilton Bayfront in
AbCellera Reports Q1 2025 Business Results
AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025
AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer ResearchⓇ (AACR) 116th Annual Meeting at the
AbCellera to Participate at Upcoming Investor Conferences in May and June
AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:
-
Bloom Burton & Co. Healthcare Investor Conference, May 5-6
-
Goldman Sachs 46th
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
AbCellera (Nasdaq: ABCL) will announce its first quarter 2025 financial results on Thursday, May 8, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
AbCellera (Nasdaq: ABCL) today announced an upcoming poster presentation that includes preclinical in vivo data on its PSMA x CD3 T-cell engagers at the American Association for Cancer ResearchⓇ
AbCellera Reports Full Year 2024 Business Results
AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
“In
AbCellera to Participate at Upcoming Investor Conferences in March
AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:
-
45th Annual TD Cowen Health Care Conference, March 3-5
-
KeyBanc Capital
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
AbCellera (Nasdaq: ABCL) will announce its full year 2024 financial results on Thursday, February 27, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time)
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery of T-cell engagers (TCE) in oncology. The expansion